SLDB Solid Biosciences Inc

Scott+Scott Attorneys at Law LLP Announces the Filing of Investor Class Action Lawsuit Against Solid Biosciences Inc.

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Solid Biosciences Inc. (“Solid Biosciences” or the “Company”) (NASDAQ:SLDB) and certain of its officers and directors for alleged violations of federal securities laws. If you acquired common stock of Solid Biosciences pursuant and/or traceable to the Company’s January 25, 2018 initial public offering (“IPO”) and/or acquired stock between January 25, 2018 and March 14, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information.

Solid Biosciences is a biotechnology company that develops therapies and devices for patients with duchenne muscular dystrophy (“DMD”).

The lawsuit alleges that Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; (2) Solid Biosciences misled investors regarding the toxicity of SGT-001; and (3) as a result of the foregoing, Defendants’ statements in the Registration Statement regarding Solid Biosciences’ business, operations, and prospects, were materially false and/or misleading.

On March 14, 2018, the Company announced it received notification from the U.S. Food and Drug Administration (“FDA”) that IGNITE DMD, its Phase I/II clinical trial for SGT-001 microdystrophin gene transfer in DMD, had been placed on Clinical Hold.

On this news, shares of Solid Biosciences fell $16.99 per share – over 64% – to close at $9.32 on March 15, 2018.

The Company held its IPO on January 26, 2018 at $16 per share; since then, the stock price has fallen nearly 47% as of market close on March 21, 2018.

What You Can Do

If you purchased Solid Biosciences securities in the IPO, or acquired stock between January 25, 2018 and March 14, 2018, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Joe Pettigrew at (844) 818-6982, or at [email protected]. Investors have until May 28, 2018, to move for lead plaintiff.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising

EN
28/03/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Solid Biosciences Inc

 PRESS RELEASE

Solid Biosciences Announces Positive Feedback from Type C Meeting with...

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - IMPACT DUCHENNE: Company aligned with FDA on Phase 3 randomized, double-blind, placebo-controlled trial design -- IMPACT DUCHENNE: Company anticipates first participant dosing in Q1 2026 - - Company plans for additional meetings with the FDA in 1H 2026 to align on a potential accelerated approval pathway for SGT-003 - - INSPIRE DUCHENNE: SGT-003 continues to be generally well tolerated with 36 participants dosed as of February 9, 2026, in Phase 1/2 trial - ...

 PRESS RELEASE

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biote...

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 CHARLESTOWN, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:30 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website...

 PRESS RELEASE

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and...

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 - Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well tolerated using a steroid-only prophylactic immunomodulation regimen - - Duchenne: First participant enrolled in IMPACT DUCHENNE, a Phase 3 randomized, double-blind, placebo-controlled, ex-U.S. clinical trial, with dosing expected in Q1 2026 - - FA: First participant dosed in Phase 1b FALCON cli...

 PRESS RELEASE

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dua...

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia - SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment - CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardi...

 PRESS RELEASE

Solid Biosciences Doses First Participant in First-in-Class Phase 1b F...

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia Initial data from the Phase 1b FALCON trial expected in H2 2026, subject to participant enrollment CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-hum...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch